Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 309.43 (+9.40), GRUB: 31.01 (-2.78), XBI: 251.78 (-3.60), IBB: 373.58 (-4.00), REGN: 540.03 (-1.82), CELG: 132.56 (-2.34)
1 ETF That’s Crushing Even Warren Buffett
George Budwell, The Motley Fool - Motley Fool - Sat Jul 25, 6:07AM CDT
Source: Flickr via Fortune Live Media Berkshire Hathaway is a legendary holding company among investors due to its 50-year history of averaging a staggering 19% annual return . To put this amazing feat into context, Berkshire's average annual...
GILD: 110.54 (-2.29), IBB: 373.58 (-4.00), CELG: 132.56 (-2.34)
SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 4.11% Loss
Comtex SmarTrend(R) - Fri Jul 24, 4:14PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $375.96 to a high of $389.00. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $388.91 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 373.58 (-4.00)
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Rebound after Yesterday's 4.11% Sell Off
Comtex SmarTrend(R) - Fri Jul 24, 4:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $375.96 to a high of $389.00. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $388.91 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 373.58 (-4.00)
Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target
Marketwired - Thu Jul 23, 8:01AM CDT
Vista Partners announced today that it has initiated coverage on Immune Pharmaceuticals Inc. (NASDAQ: IMNP); with a twelve-month price target of $6.00. Ross Silver, Principal Analyst at Vista Partners, stated, "Immune Pharmaceuticals Inc. ('IMNP'
IBB: 373.58 (-4.00), IMNP: 1.74 (-0.10), CELGZ: 2.00 (-0.06)
iShares Nasdaq Biotechnology Index Fund (IBB) : Take profit @ $390
Trading Central - Wed Jul 15, 1:54PM CDT
A gravestone doji is taking place, calling for a trend reversal. We close our long position @ 390. Performance: +3.28%.
IBB: 373.58 (-4.00)
These 2 Biotech Stocks Cratered in 2015 -- Is 1 Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Wed Jul 15, 9:04AM CDT
Source: Cancer Institute of Columbia For the most part, biotech stocks have been having a great 2015. The iShares Nasdaq Biotech Index , for instance, has essentially clobbered the broader markets so far this year: Per usual, however,...
IBB: 373.58 (-4.00), AAVL: 14.29 (-0.44), PBYI: 84.69 (-4.60)
'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 94.17 (-2.78), FBT: 123.85 (-1.42), XBI: 251.78 (-3.60), AMGN: 165.54 (+6.95), IBB: 373.58 (-4.00), INTC: 28.35 (+0.29), CELG: 132.56 (-2.34), NFLX: 106.43 (-2.91), SPY: 206.79 (-1.21), GILD: 110.54 (-2.29), KITE: 68.86 (+0.14), RCPT: 227.09 (-0.91), JUNO: 47.80 (-2.36), TWTR: 34.70 (-0.72), AAPL: 122.77 (-1.73), Z: 76.91 (-2.64)
As Biotech Beats, 6 Top ETF Picks For Rest Of 2015
at Investor's Business Daily - Tue Jul 14, 5:38PM CDT
Biotechnology and pharmaceutical ETFs powered ahead in the past month, handing profits-on-steroids to investors. A wave of mergers, robust pipelines and busier-than-ever hospitals continue to drive these industries forward. The iShares Nasdaq...
SPY: 206.79 (-1.21), EFAV: 66.24 (-0.36), OIL: 9.22 (-0.26), AGG: 109.26 (+0.14), ILMN: 217.27 (-3.83), IBB: 373.58 (-4.00), SHY: 84.85 (+0.06), VNQ: 78.21 (+0.14), FV: 24.65 (-0.23), SDY: 75.93 (-0.17)
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015 - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 8:30AM CDT
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015
XOP: 37.44 (-1.15), XT: 25.25 (-0.25), UBIO: 18.24 (-0.67), XBI: 251.78 (-3.60), IBB: 373.58 (-4.00), LABU: 46.23 (-2.40), ZBIO: 20.79 (+0.66), CHAD: 48.76 (+3.96), YLCO: 13.34 (+0.15), LABD: 30.37 (+1.20), DRIP: 83.98 (+6.73), ASHR: 39.16 (-3.95), GUSH: 16.27 (-1.59)
iShares Nasdaq Biotechnology Index Rises 1.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 13, 4:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 373.58 (-4.00)
Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 1.63% Yesterday
Comtex SmarTrend(R) - Mon Jul 13, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 373.58 (-4.00)
It's Time for Investors to Focus on Individual Stocks, Not Macro Events
at The Street - Mon Jul 13, 1:42PM CDT
The 'Fast Money Halftime' trading panel says that in this weak macro market, momentum stocks, individual companies and specific sectors should be the theme for investors, not broad-based index funds.
FIT: 43.93 (-1.61), GREK: 9.33 (-0.42), XBI: 251.78 (-3.60), C: 57.96 (-0.74), IBB: 373.58 (-4.00), BAC: 17.67 (-0.23), TLT: 122.04 (+0.65), MS: 39.25 (-0.35), NFLX: 106.43 (-2.91), SPY: 206.79 (-1.21), GS: 205.02 (-2.33), JPM: 68.01 (-0.90), QQQ: 110.18 (-0.92), DIA: 174.23 (-1.29), IWM: 120.57 (-1.01), XLF: 24.94 (-0.18)
Trader's Notebook: Transport ETF Could Bounce Back
at The Street - Thu Jul 09, 8:00AM CDT
The iShares Transportation Average ETF (IYT) has suffered in recent months, but may finally be nearing a bit of support.
YANG: 92.20 (+9.72), IBB: 373.58 (-4.00), YINN: 27.66 (-3.66), IYT: 144.41 (-0.22), FXI: 40.13 (-1.61)
iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 2.85%
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 373.58 (-4.00)
After Yesterday's Decline of 2.85%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 373.58 (-4.00)
3 Stocks to Buy in a Market Crash
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 08, 10:55AM CDT
The last five years have been an absolute dream particularly for biotech investors; shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) have scorched the returns of the market over that time period, up more than 400% when the...
ISIS: 53.68 (+0.53), GILD: 110.54 (-2.29), IBB: 373.58 (-4.00), CELG: 132.56 (-2.34)
Uncertainty Escalates After Greek Referendum
David Fry - at Seeking Alpha - Mon Jul 06, 11:14PM CDT
At this point words fail me once again. What will happen to Greece and their EU partners, no one knows. For now it's a cancer growing on both Greece and many world stock indexes. China is more alarming after the PBOC intervened in markets to no...
XLB: 44.58 (-0.50), GREK: 9.33 (-0.42), IBB: 373.58 (-4.00), EWO: 16.15 (-0.15), TLT: 122.04 (+0.65), EEM: 36.36 (-0.70), XLP: 49.65 (-0.03), SPY: 206.79 (-1.21), ITB: 27.09 (-0.08), IYR: 74.11 (+0.16), XLI: 52.64 (-0.26), SLV: 13.92 (-0.10), FXE: 108.90 (+1.15), XLF: 24.94 (-0.18), GDX: 13.57 (-0.51), JJC: 27.59 (-0.54), XLE: 68.51 (-1.00), FXI: 40.13 (-1.61), USO: 15.65 (-0.38), DBC: 15.83 (-0.31), DBA: 21.33 (-0.37), XLY: 78.26 (-0.59), FXY: 78.76 (+0.35), EZU: 38.10 (-0.35), XLU: 42.87 (+0.54), HAO: 26.11 (-1.99), UUP: 25.25 (-0.20), XRT: 96.33 (-0.81), XLV: 74.78 (-0.07), IEV: 43.83 (-0.35), GLD: 104.86 (-0.49), EPI: 21.52 (-0.41), RSX: 16.52 (-0.43), EFA: 63.42 (-0.47), EWZ: 28.05 (-0.45)
The Medicines Company Is Rallying Despite Unfavorable Ruling In Patent Case
Emerging Equities - at Seeking Alpha - Mon Jul 06, 6:51PM CDT
MDCO: 33.39 (-0.43), MYL: 56.37 (-9.57), IBB: 373.58 (-4.00)
Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th!
SA Editor Mike Taylor - Seeking Alpha - Thu Jul 02, 3:00PM CDT
A holiday-shortened week still left biotech investors with plenty to chew over. The start of a decade-long collaboration between Celgene ( CELG ) and Juno Therapeutics ( JUNO ) prompted a new wave of enthusiasm for an already well appreciated CAR-T...
CRMD: 3.28 (-0.23), SGYP: 8.19 (+0.28), MNK: 123.08 (-0.74), BIIB: 309.43 (+9.40), OCAT: 4.63 (-0.06), VRX: 257.30 (+5.38), PRGO: 193.60 (+7.10), VRTX: 123.23 (-2.27), GALT: 2.63 (-0.06), IBB: 373.58 (-4.00), MNKD: 4.77 (-0.21), HNT: 65.60 (-0.07), CELG: 132.56 (-2.34), CNC: 69.10 (+0.06), JNJ: 98.28 (-0.87), MDCO: 33.39 (-0.43), GILD: 110.54 (-2.29), GERN: 4.08 (-0.03), JUNO: 47.80 (-2.36), BXLT: 30.60 (-0.29), EXEL: 5.44 (-0.15), NVS: 101.54 (-0.26)